Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Key Points

Biotech stocks have a reputation for being high risk, high reward.
Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
5 stocks we like better than Denali Therapeutics

Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

→ A new way to collect income from stocks (From DTI) (Ad)

Should you invest $1,000 in Denali Therapeutics right now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Denali Therapeutics (DNLI)	3.6045 of 5 stars	$15.56	-3.4%	N/A	-14.41	Buy	$41.22
Ultragenyx Pharmaceutical (RARE)	4.4295 of 5 stars	$44.28	-1.8%	N/A	-5.32	Moderate Buy	$90.33
Sarepta Therapeutics (SRPT)	4.875 of 5 stars	$124.25	+6.1%	N/A	-20.30	Moderate Buy	$158.38
Pfizer (PFE)	4.995 of 5 stars	$26.26	-0.2%	6.40%	72.94	Hold	$36.33
Exelixis (EXEL)	4.9768 of 5 stars	$23.71	+1.8%	N/A	37.05	Moderate Buy	$26.29
Moderna (MRNA)	4.0555 of 5 stars	$108.85	+0.9%	N/A	-8.77	Hold	$126.49
United Therapeutics (UTHR)	4.407 of 5 stars	$237.00	+1.1%	N/A	11.95	Moderate Buy	$294.25
Biogen (BIIB)	4.9222 of 5 stars	$201.99	+4.6%	N/A	25.31	Moderate Buy	$295.58
Sanofi (SNY)	3.0661 of 5 stars	$46.61	-2.3%	2.96%	19.75	Hold	$55.00
Eli Lilly and Company (LLY)	4.8402 of 5 stars	$732.20	-1.8%	0.71%	126.24	Moderate Buy	$728.05